HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Coatney, G. R. Articles by Lunn, J. S. Search for Related Content PubMed PubMed Citation Articles by Coatney, G. R. Articles by Lunn, J. S.

Further Observations on the Antimalarial Activity of CI-501 (Camolar®) against the Chesson Strain of Vivax Malaria

A repository preparation of the dihydrotriazine metabolite of chlorguanide (proguanil), known as CI-501 (Camolar®), was tested in 24 prisoner volunteers for its effectiveness as an antimalarial drug.

The 24 premedicated volunteers were challenged 1 to 10 times by the bites of Anopheles quadrimaculatus mosquitoes heavily infected with the Chesson strain of vivax malaria. As of 24 November 1963, 12 of the 24 volunteers have developed patent infections 169 to 586 days after medication or 13 to 434 days after their last exposure to infection. The remaining 12 volunteers continue to show no evidence of infection 619 to 730 days (20 to 24 months) after medication.

These results indicate that this preparation has the capacity to exert long-term protection against vivax malaria. The importance of such a preparation in a program of world-wide malaria eradication is stressed.

^* Hospital, U. S. Penitentiary, Atlanta, Georgia.